Fabio Cataldi

1.5k citations

72 papers · 1.0k indexed · 1 hit paper · h-index 15

Impact in

Genetics top 5%
- Inflammatory Bowel Disease
Immunology top 10%
- Immunodeficiency and Autoimmune Disorders
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction

Papers in ⓘ

Gastroenterology 11
Genetics 48
- Inflammatory Bowel Disease 48
- Chronic Lymphocytic Leukemia Research 7

Co-authors: Walter Reinisch (21 shared papers)William J. Sandborn (24 shared papers)Silvio Danese (28 shared papers)Mina Hassan‐Zahraee (7 shared papers)Séverine Vermeire (24 shared papers)Julián Panés (9 shared papers)Stefan Schreiber (20 shared papers)Geert D’Haens (16 shared papers)
Journals: Journal of Crohn s and Colitis (26 papers)Gastroenterology (17 papers)The American Journal of Gastroenterology (8 papers)Inflammatory Bowel Diseases (5 papers)Gut (2 papers)
Partner nations: United States Italy France

In The Last Decade

Fabio Cataldi

71 papers receiving 1000 citations

Hit Papers

align trajectories log scale

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies 2023 · 190 citations

Peers

Countries citing papers authored by Fabio Cataldi

Since Specialization

Citations

This map shows the geographic impact of Fabio Cataldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Cataldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Cataldi more than expected).

Fields of papers citing papers by Fabio Cataldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Cataldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Cataldi. The network helps show where Fabio Cataldi may publish in the future.

Co-authors

The 25 scholars most cited alongside Fabio Cataldi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fabio Cataldi Line = papers co-authored together Fabio Cataldi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 72 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies The Lancet ·William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Julián Panés, Andrés Yarur, Timothy E. Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert D’Haens, Silvio Danese, Martina Goetsch, Brian G. Feagan Hit paper breakdown →	2023	190
2	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial The Lancet ·Séverine Vermeire, William J. Sandborn, Silvio Danese, Xavier Hébuterne, Bruce Salzberg, Maria Kłopocka, Dino Tarabar, Tomáš Vaňásek, Miloš Greguš, Paul Hellstern, Joo Sung Kim, Miles Sparrow, Kenneth J. Gorelick, Michelle Hinz, Alaa Ahmad, Vivek Pradhan, Mina Hassan‐Zahraee, Robert Clare, Fabio Cataldi, Walter Reinisch	2017	146
3	Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study Gut ·Walter Reinisch, Julián Panés, Sunil Khurana, Gábor Tóth, Fei Hua, Gail M. Comer, Michelle Hinz, Karen Page, Margot O’Toole, Tara McDonnell Moorehead, Huachen Zhu, Yanhui Sun, Fabio Cataldi	2015	123
4	Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study Gut ·William J. Sandborn, Scott D. Lee, Dino Tarabar, Édouard Louis, Maria Kłopocka, Jochen Klaus, Walter Reinisch, Xavier Hébuterne, Dong Il Park, Stefan Schreiber, Satyaprakash Nayak, Alaa Ahmad, Anindita Banerjee, Lisa Brown, Fabio Cataldi, Kenneth J. Gorelick, John B. Cheng, Mina Hassan‐Zahraee, Robert Clare, Geert D’Haens	2017	86
5	Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1 Journal of Crohn s and Colitis ·Walter Reinisch, Kenneth E. Hung, Mina Hassan‐Zahraee, Fabio Cataldi	2018	44
6	A pharmacokinetic comparison of anrukinzumab, an anti‐ IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients British Journal of Clinical Pharmacology ·Fei Hua, Jakob Ribbing, Walter Reinisch, Fabio Cataldi, Steven W. Martin	2015	39
7	Influence of advanced age and related comorbidity on the course and outcome of acute pancreatitis. PubMed ·Generoso Uomo, G. Talamini, Rabitti Pg, Fabio Cataldi, A Cavallera, F. Rengo	1998	32
8	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II Journal of Crohn s and Colitis ·Walter Reinisch, William J. Sandborn, Silvio Danese, Xavier Hébuterne, Maria Kłopocka, Dino Tarabar, Tomáš Vaňásek, Miloš Greguš, Paul Hellstern, Joo Sung Kim, Miles Sparrow, Kenneth J. Gorelick, Michael Hoy, Martina Goetsch, Caleb Bliss, Charu Gupta, Fabio Cataldi, Séverine Vermeire	2021	25
9	Does meniscus removal affect ACL‐deficient knee laxity? An in vivo study Knee Surgery Sports Traumatology Arthroscopy ·Stefano Zaffagnini, Cecilia Signorelli, Tommaso Bonanzinga, Alberto Grassi, Hernán Galán, Ibrahim Akkawi, Laura Bragonzoni, Fabio Cataldi, Maurilio Marcacci	2016	25
10	Autotransfusion in major orthopaedic surgery: experience with 1785 patients British Journal of Anaesthesia ·Battista Borghi, Elettra Pignotti, M. Montebugnoli, Ana Paula Farnezi Bassi, M Corbascio, N. De Simone, K Elmar, U. Righi, A. M. Laguardia, S Bugamelli, Fabio Cataldi, R Ranocchi, M. A. Feoli, Tonino Bombardini, G Gargioni, Andrea Franchini, Guido Caroli	1997	24
11	Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE) Neurogastroenterology & Motility ·Lin Chang, Brooks D. Cash, Anthony Lembo, David C. Kunkel, Brett A. English, Beatriz Lindstrom, Guibao Gu, Sharon Skare, Kye Gilder, Stewart A. Turner, Fabio Cataldi, Donald Lipkis, Jan Tack	2023	23
12	901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study Gastroenterology ·Walter Reinisch, William J. Sandborn, Silvio Danese, Fabio Cataldi, Xavier Hébuterne, Bruce Salzberg, Maria Kłopocka, Dino Tarabar, Tomáš Vaňásek, Miloš Greguš, Paul Hellstern, Joo Sung Kim, Miles Sparrow, Kenneth J. Gorelick, Michelle Hinz, Alaa Ahmad, Mina Hassan‐Zahraee, Vivek Pradhan, Séverine Vermeire	2015	21
13	Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn’s Disease Journal of Crohn s and Colitis ·Mina Hassan‐Zahraee, Anindita Banerjee, John B. Cheng, Weidong Zhang, Alaa Ahmad, Karen Page, David von Schack, Baohong Zhang, Steven W. Martin, Satyaprakash Nayak, Padma Reddy, Xi Li, Hendrik Neubert, Mireia Fernández Ocaña, Ken Gorelick, Robert Clare, Michael S. Vincent, Fabio Cataldi, Kenneth E. Hung	2017	21
14	P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy Journal of Crohn s and Colitis ·Geert D’Haens, Marla C. Dubinsky, Laurent Peyrin‐Biroulet, Silvio Danese, B E Sands, Douglas C. Wolf, Andrés Yarur, Michael Chiorean, D Dray, Irene Modesto, Huaming Tan, G Gu, Ciro Lopez, Chunyan Su, J Zhang, Fabio Cataldi, A McDonnell, Stefanie Schreiber, B G Feagan, Séverine Vermeire	2023	14
15	Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study Geert D’Haens, S. Lee, Dino Tarabar, E Louis, Maria Kłopocka, D. I. Park, Jules J. Claus, Xavier Hébuterne, Walter Reinisch, Stefan Schreiber, Ken Gorelick, John Cheng, M. Hassan-Zahraee, L. M. Brown, A. Ahmad, Ansuman Banerjee, Fabio Cataldi, W. Sandborn	2015	14
16	OP022 Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study Journal of Crohn s and Colitis ·Stefan Schreiber, Laurent Peyrin‐Biroulet, Brigid S. Boland, Peter Higgins, Alessandro Armuzzi, Jonathan P. Terdiman, Wen Zhou, Gabriela Alperovich, Fabio Cataldi, S Goteti, Ana P. Lacerda	2018	13
17	825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study Gastroenterology ·William Sandborn, Scott D. Lee, Dino Tarabar, Édouard Louis, Maria Kłopocka, Jochen Klaus, Walter Reinisch, Xavier Hébuterne, Dong Il Park, Stefan Schreiber, Kenneth J. Gorelick, Mina Hassan‐Zahraee, Lisa Brown, Alaa Ahmad, John B. Cheng, Fabio Cataldi, Geert D’Haens	2015	13
18	Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study Inflammatory Bowel Diseases ·Geert D’Haens, Walter Reinisch, Scott D. Lee, Dino Tarabar, Édouard Louis, Maria Kłopocka, Jochen Klaus, Stefan Schreiber, Dong Il Park, Xavier Hébuterne, Péter Nagy, Fabio Cataldi, Steven W. Martin, Satyaprakash Nayak, Anindita Banerjee, Kenneth J. Gorelick, William J. Sandborn	2021	11
19	Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target Expert Review of Clinical Immunology ·Mariangela Allocca, Gionata Fiorino, Séverine Vermeire, Walter Reinisch, Fabio Cataldi, Silvio Danese	2014	10
20	799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve Gastroenterology ·Remo Panaccione, Geert D’Haens, William J. Sandborn, Subrata Ghosh, Stefan Schreiber, Satoshi Tanida, Wen Zhou, Fabio Cataldi, David Pugatch, Bidan Huang, Wangang Xie, Peter Higgins	2019	10

About Fabio Cataldi

Fabio Cataldi is a scholar working on Gastroenterology, Genetics, Immunology, Epidemiology and Genetics, having authored 72 papers that have together received 1.0k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (48 papers), Microscopic Colitis (32 papers), Helicobacter pylori-related gastroenterology studies (11 papers), Eosinophilic Esophagitis (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Immunodeficiency and Autoimmune Disorders (7 papers), IL-33, ST2, and ILC Pathways (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). The work is most often cited by research in Genetics (632 citations), Immunology (364 citations), Gastroenterology (82 citations), Immunology and Allergy (67 citations) and Hematology (104 citations). Fabio Cataldi has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Walter Reinisch, William J. Sandborn, Silvio Danese, Mina Hassan‐Zahraee, Séverine Vermeire, Julián Panés, Stefan Schreiber, Geert D’Haens, Maria Kłopocka and Michelle Hinz. Their work appears in journals such as Journal of Crohn s and Colitis, Gastroenterology, The American Journal of Gastroenterology, Inflammatory Bowel Diseases and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact